Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) was up 5.7% on Wednesday . The stock traded as high as $20.16 and last traded at $20.16. Approximately 7,396 shares changed hands during trading, a decline of 95% from the average daily volume of 152,312 shares. The stock had previously closed at $19.07.
Rapport Therapeutics Stock Down 1.3 %
The stock has a 50-day simple moving average of $23.12.
Hedge Funds Weigh In On Rapport Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in RAPP. Values First Advisors Inc. acquired a new position in shares of Rapport Therapeutics during the third quarter worth $31,000. BNP Paribas Financial Markets acquired a new position in Rapport Therapeutics during the 3rd quarter worth about $34,000. SG Americas Securities LLC bought a new stake in shares of Rapport Therapeutics in the 3rd quarter valued at about $101,000. Sandia Investment Management LP acquired a new stake in shares of Rapport Therapeutics in the second quarter valued at about $116,000. Finally, MetLife Investment Management LLC bought a new position in shares of Rapport Therapeutics during the third quarter worth about $117,000.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
